Palisade Bio Prices $120M Public Offering of 171M Shares

Palisade Bio, a clinical-stage biopharmaceutical company specializing in therapeutics for autoimmune, inflammatory, and fibrotic diseases, has priced a significant public offering to raise approximately $120 million by selling 171.4 million shares at $0.70 each. Ladenburg Thalmann & Co. is serving as the sole book-running manager for the offering, which includes a 45-day option for underwriters to purchase an additional 25.7 million shares. This capital raise aims to support Palisade's development of treatments like PALI-2108 for inflammatory bowel disease, amid ongoing financial challenges with no current revenue and substantial operating losses. The offering is expected to close around October 2, 2025, subject to customary closing conditions and SEC approvals. The company’s market capitalization stands at roughly $9.7 million, reflecting the early-stage nature of its biotech operations and reliance on funding for research and development. The registration statements for the offering have been filed and declared effective by the SEC, ensuring regulatory compliance for this funding round.